DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reclipsen (Desogestrel / Ethinyl Estradiol) - Published Studies

 
 



Reclipsen Related Published Studies

Well-designed clinical trials related to Reclipsen (Desogestrel / Estradiol)

Desogestrel+ethinylestradiol versus levonorgestrel+ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change. [2011.01]

Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. [2009.07]

Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. [2009.02]

Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. [2007.12]

A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. [2006.04]

Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. [2005.06]

Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene. [2004.06]

A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. [2004.04]

Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. [2003.08]

A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. [2003.06]

Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. [2002.12]

Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. [2002.12]

Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. [2002.01]

Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. [2001.09]

Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. [2001.07]

Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. [2001.03]

Latin american experience with two low-dose oral contraceptives containing 30 microg ethinylestradiol/75 microg gestodene and 20 microg ethinylestradiol/150 microg desogestrel. [2000.09]

A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. [2000.07]

Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. [2000.07]

Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. [2000.07]

Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. [2000.05]

Single monthly administration of the anti-progestagen Org 31710 in users of the 75 microg desogestrel progestagen-only pill: effects on pituitary-ovarian activity. [2000.03]

A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. [2000.02.15]

A comparative study of the effects of two oral contraceptives containing dienogest or desogestrel on the human immune system. [2000.02]

A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. [1999.11]

Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta. [1999.10]

A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. [1999.09]

Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. [1999.05]

A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. [1999.04]

Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene. [1999]

A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. [1998.12]

Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. [1998.09]

Well-designed clinical trials possibly related to Reclipsen (Desogestrel / Estradiol)

A randomized controlled trial of NuvaRing versus combined oral contraceptive pills for pretreatment in in vitro fertilization cycles. [2011.09]

Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. [2011.09]

20 microg versus >20 microg estrogen combined oral contraceptives for contraception. [2011.01.19]

Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. [2010.09]

Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system 'NuvaRing' as compared with the standard 21/7 regime in reproductive-age women with type 1 diabetes mellitus. [2010.09]

An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. [2010.05]

Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. [2010.03]

Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. [2010.03]

Sexual function in first-time contraceptive ring and contraceptive patch users. [2010.01]

[Combined hormonal contraception in cycles artificially extended]. [2010.01]

Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. [2010]

Treatment of clomiphene citrate-related ovarian cysts in a prospective randomized study. A single center experience. [2009.10]

A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. [2009.08]

[Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy chinese women: a multicenter randomized controlled trial] [2009.01]

20 microg versus >20 microg estrogen combined oral contraceptives for contraception. [2008.10.08]

Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. [2008.09]

Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. [2008.08]

Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. [2008.02]

Use of the NuvaRing(R) hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus. [2008.02]

The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. [2008.02]

Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use. [2007.11]

7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. [2007.09]

Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. [2007.02]

Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. [2007.01]

Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. [2006.12]

Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. [2006.09]

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. [2006.09]

Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. [2006.05.20]

Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. [2006.04]

Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. [2006.03.20]

Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. [2006.01]

A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. [2006.01]

A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. [2006.01]

Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. [2005.11]

Extended regimens of the contraceptive vaginal ring: a randomized trial. [2005.09]

Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. [2005.05]

20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. [2005.04.18]

Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. [2005.04]

A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. [2005.02]

Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. [2005]

Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]

Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]

Effects of hormonal contraception on bone mineral density after 24 months of use. [2004.05]

Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. [2004.04]

The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. [2004.03]

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. [2004.02.01]

Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives. [2004.02]

The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. [2004.02]

Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. [2003.12]

Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. [2003.10]

A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. [2003.05]

Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. [2003.05]

The combined contraceptive ring NuvaRing and spermicide co-medication. [2003.04]

The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. [2003.03]

Complete and robust ovulation inhibition with NuvaRing. [2002.12]

Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. [2002.08]

Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction. [2002.08]

Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. [2002.07]

[Ultrasonographic and lipid changes in polycystic ovary syndrome according to the type of treatment ] [2002.06]

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. [2002.05]

Serum concentrations of markers of type I collagen metabolism in women taking monophasic oral contraceptives. [2002.02]

Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. [2002.02]

Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. [2002.01]

Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. [2001.11]

Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. [2001.10]

The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. [2001.10]

Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women. [2001.09.28]

A scheme of combined oral contraceptives for women more than 40 years old. [2001.07]

Ovarian function during and after treatment with the new progestagen Org 30659. [2001.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017